70 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 CPHI FRANKFURT CPHI has been a cornerstone in developing Axplora’s reputation in pharma. It’s where our identity as a reliable, high-performing partner is reinforced year after year. More than just being visible, it’s about being part of a global conversation on how to accelerate access to life-changing medicines. At CPHI, trust is built through presence, consistency, and meaningful engagement. The companies that stand out don’t just show up, they show substance. They speak to real market needs, demonstrate technical excellence, and, most importantly, show how they solve complexity. That’s been Axplora’s edge: speed, reliability, and a “dare to imagine” mindset that drives partnership, not just transactions. For a first-time attendee, I’d say, don’t underestimate the power of listening. Ask real questions. Seek to understand where you can genuinely add value. The most lasting connections come from shared purpose, not sales pitches. A moment that stands out for me is being struck after my first CPHI was how much I hadn’t seen, even after a full week. The sheer scale was a reminder of just how interconnected our industry is in driving access to lifechanging medicines. For Axplora, that’s what CPHI is about: showing up with purpose, listening deeply, and partnering to shape global health solutions. You’ve spent years building your brand in pharma, how has CPHI helped you shape long-term reputation and trust in the industry? MARTIN MEESON CEO Axplora PAOLINA TOBOŁA Analytics Development Division Manager Mabion
RkJQdWJsaXNoZXIy MjY2OTA4MA==